Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase…
<!-- Name:DistributionId Value:8843154 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Rencofilstat
Hepion Pharmaceuticals to Deliver Updates on Ongoing Phase 2 NASH Clinical Program…
<!-- Name:DistributionId Value:8780828 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Anti-Cancer Potential of Rencofilstat Expanded with Results from Preclinical Multiple…
- Synergistic activity demonstrated with rencofilstat in combination with first line multiple myeloma drug, bortezomib - EDISON, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Hepion…
Presentation of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat…
EDISON, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven…
Hepion Pharmaceuticals to Present Phase 2a Rencofilstat Multiomics Data at NASH-TAG…
EDISON, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven…
Hepion Pharmaceuticals Announces Publication of Food Effect Study with Rencofilstat
EDISON, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven…
Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat…
EDISON, N.J., June 20, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven…
Hepion Pharmaceuticals Announces USAN Selection of “Rencofilstat” as Nonproprietary…
EDISON, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven…